Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | METAP1 | P53582 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | MMP14 | P50281 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011684 | 0.77 | ALDH1A1 (0.40) | ALDH1A1PLAUMAPTKMT2AMEN1 | |
| SCHEMBL15005588 | 0.77 | ALDH1A1 (0.40) | ALDH1A1PLAUMAPTKMT2AMEN1 | |
| SCHEMBL30723280 | 0.76 | IDO1 (0.50) | ALDH1A1KDM4EPOLBCYP1A2MAPT | |
| SCHEMBL30827855 | 0.76 | ALDH1A1 (0.55) | ALDH1A1KDM4EPOLBPLAUCYP1A2 | |
| SCHEMBL10642216 | 0.76 | IDO1 (0.50) | ALDH1A1KDM4EPOLBCYP1A2MAPT | |
| SCHEMBL196720 | 0.76 | ALDH1A1 (0.55) | ALDH1A1KDM4EPOLBPLAUCYP1A2 | |
| SCHEMBL12055251 | 0.74 | CYP1A2 (0.54) | ALDH1A1KDM4ECYP1A2CYP2A6MAPT | |
| SCHEMBL25390154 | 0.74 | TNF (0.37) | ALDH1A1KDM4EPOLBPLAUCYP1A2 | |
| SCHEMBL13074891 | 0.74 | PLG (0.43) | ALDH1A1KDM4EPLAUMAPTLMNA | |
| SCHEMBL5398756 | 0.73 | PLAU (0.52) | ALDH1A1KDM4EPLAUCYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2025-04-01 | — | — | US | disclosed |
| WO-2025056017-A1 | FUSED BICYCLIC HETEROARYLS AS PARG INHIBITORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2025-03-20 | — | — | WO | disclosed |
| CN-111116555-B | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
| EP-3878846-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| EP-3878846-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | Beijing Increase Innovative Drug Co., Ltd. (CN) | 2021-09-15 | — | — | EP | disclosed |
| EP-3354643-B1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS INC (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-111116555-A | Rho kinase inhibitor and preparation method and application thereof | 北京盈科瑞创新药物研究有限公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-3354643-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3053913-B1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2691393-B1 | NOVEL BICYCLIC PYRIDINONES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9067934-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-1684787-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8697673-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140045790-A1 | Novel Bicyclic Pyridinones | PFIZER INC. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2691393-A1 | NOVEL BICYCLIC PYRIDINONES | Pfizer Inc (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | PFIZER INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012131539-A1 | NOVEL BICYCLIC PYRIDINONES | PFIZER INC. (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | ROCK1, RHOA, ROCK2 | ALDH1A1 4142/4885KDM4E 2101/4885POLB 3851/4885 |
| US-20140045790-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2C19, CYP2D6 | ALDH1A1 268/4885KDM4E 2745/4885POLB 1594/4885 |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2C19, CYP2D6 | ALDH1A1 268/4885KDM4E 2745/4885POLB 1594/4885 |
| US-12264146-B2 | Rho kinase inhibitor, method for preparing same and uses thereof | ROCK1, RHOA, ROCK2 | ALDH1A1 4142/4885KDM4E 2101/4885POLB 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.